Home / Congenital and Juvenile-Onset Clinical Trial Launches

Congenital and Juvenile-Onset Clinical Trial Launches

AMO Pharma Limited (AMO Pharma) announced initiation of a phase 2 clinical study in the U.K. for AMO-02 (tideglusib) on August 10, 2016. This phase 2 exploratory study focuses on adult and adolescent patients with congenital and juvenile onset myotonic dystrophy. This is the first sponsor-led clinical study evaluating an investigational therapy in this patient group as part of a development program. 

For AMO Pharma's announcement on the clinical trial, click here. Click here for more detail on the trial at clinicaltrials.gov. For more information on AMO Pharma, click here.

Partners

© Myotonic Dystrophy Foundation. All rights reserved.